Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells

被引:0
|
作者
Malin Dahl
Pierre Bouchelouche
Gabriela Kramer-Marek
Jacek Capala
Jørgen Nordling
Kirsten Bouchelouche
机构
[1] University of Copenhagen,Cancer and Molecular Imaging Unit, Research Division of Clinical Biochemistry
[2] Koege Hospital,Molecular Targeting Section, Radiation Oncology Branch, Center for Cancer Research
[3] National Cancer Institute,Department of Urology
[4] National Institutes of Health,PET and Cyclotron Unit, Rigshospitalet
[5] Herlev Hospital,undefined
[6] University of Copenhagen,undefined
[7] University of Copenhagen,undefined
来源
Molecular Biology Reports | 2011年 / 38卷
关键词
HER2/neu; LNCaP; Prostate cancer; Sarcosine;
D O I
暂无
中图分类号
学科分类号
摘要
Increasing evidence suggests that Human epidermal growth factor receptor 2 (HER2/neu) is involved in progression of prostate cancer. Recently, sarcosine was reported to be highly increased during prostate cancer progression, and exogenous sarcosine induces an invasive phenotype in benign prostate epithelial cells. The aim of this work was to investigate the effect of sarcosine on HER2/neu expression in prostate cancer cell lines LNCaP (androgen dependent), PC-3 and DU145 (both androgen independent). Relative amounts of HER2/neu and androgen receptor (AR) transcripts were determined using RT-qPCR. Total expression of HER2/neu was confirmed by Western blot (WB). HER2/neu protein on the surface of living LNCaP cells was visualized by confocal microscopy using a HER2/neu-specific fluorescent probe. Exposure of LNCaP cells to 50 μM sarcosine for 24 h resulted in a 58% increase of the HER2/neu mRNA level (P < 0.001) indicating that sarcosine effects HER2/neu expression on the level of transcription. Control experiments with alanine, an isomer of sarcosine, showed no significant effect on HER2/neu transcription. The upregulation of HER2/neu mRNA preceded the corresponding increment of the protein level after the 48-h exposure to sarcosine as shown by WB and confocal microscopy. Interestingly, sarcosine had no effect on the activated (phosphorylated) form of HER2/neu. No significant change in AR expression was observed after exposure to sarcosine. This is the first report indicating that sarcosine is involved in the regulation of the oncoprotein HER2/neu. Thus, sarcosine may induce prostate cancer progression by increased HER2/neu expression. However, detailed information on cellular mechanisms remains to be elucidated.
引用
收藏
相关论文
共 50 条
  • [41] EVALUATION OF HER2/NEU EXPRESSION IN BREAST CANCER BONE METASTASES
    Juan Illarramendi, Jose
    Cordoba, Alicia
    Fernandez Seara, Pilar
    Lopez Cousillas, Alfredo
    Amat, Irene
    Reparaz, Begona
    Ruiz De Azua, Geranie
    De Miguel, Concepcion
    Salgado, Esteban
    Vera, Ruth
    Munoa, Javier
    BREAST, 2011, 20 : S28 - S28
  • [42] Elevated serum her2/neu in human prostate cancer and benign hyperplasia
    Siampanopoulou, M.
    Dimasis, N.
    Galaktidou, G.
    Zaromitidou, E.
    Peftoulidis, S.
    Sioundas, A.
    Haritanti, A.
    Gotzamani-Psarrakou, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 420 - 420
  • [43] Alteration of gene expression in response to bone morphogenetic protein-2 in androgen-dependent human prostate cancer LNCaP cells
    Kumagai, T
    Tomari, K
    Shimizu, T
    Takeda, K
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2006, 17 (02) : 285 - 291
  • [44] Degradation of HER2/neu by apigenin induces apoptosis through cytochrome c release and caspase-3 activation in HER2/neu-overexpressing breast cancer cells
    Way, TD
    Kao, MC
    Lin, JK
    FEBS LETTERS, 2005, 579 (01): : 145 - 152
  • [45] Efficacy of vaccination with plasmid DNA encoding for HER2/neu or HER2/neu-EGFP fusion protein against prostate cancer in rats
    Bhattacharya, R
    Bukkapatnam, R
    Prawoko, I
    Soto, J
    Morgan, M
    Salup, RR
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2002, 2 (06) : 783 - 796
  • [46] Clinical relevance of an SRF- and androgen-dependent gene expression signature in prostate cancer
    Heemers, Hannelore
    Schmidt, Lucy
    Sun, Zhifu
    Anderson, S.
    Balman, Karla
    Tindall, Donald
    CANCER RESEARCH, 2009, 69
  • [47] Role of androgen deprivation in EGFR and Her-2/neu gene expression patterns in prostate cancer.
    Midathada, MV
    Dennis, R
    Kaushal, V
    Kohli, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 853S - 853S
  • [48] Hesperidin Suppressed Proliferations of both Human Breast Cancer and Androgen-dependent Prostate Cancer Cells
    Lee, Choong Jae
    Wilson, Leslie
    Jordan, Mary Ann
    Nguyen, Vy
    Tang, Jessica
    Smiyun, Gregory
    PHYTOTHERAPY RESEARCH, 2010, 24 : S15 - S19
  • [49] EZH2 inhibition as an effective treatment for androgen-dependent prostate cancer
    Bradley, B.
    Mcgrath, J.
    Yuan, C. C.
    Zhao, F.
    Sawant, P.
    Hatton, C.
    Han, X.
    Bryant, B.
    Conery, A.
    Trojer, P.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E120 - E121
  • [50] Solamargine induces apoptosis and enhances susceptibility to trastuzumab and epirubicin in breast cancer cells with low or high expression levels of HER2/neu
    Shiu, Li Yen
    Liang, Chia Hua
    Chang, Li Ching
    Sheu, Hamm Ming
    Tsai, Eing Mei
    Kuo, Kou Wha
    BIOSCIENCE REPORTS, 2009, 29 (01) : 35 - 45